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AbstrACt
Introduction Ovarian cancer is the leading cause of 
death from gynaecological cancer, with more than 7000 
new cases registered in the UK in 2014. In patients 
suitable for surgery, the National Institute of Health and 
Care Excellence guidance for treatment recommends 
surgical resection of all macroscopic tumour, followed by 
chemotherapy. The surgical procedure can be extensive 
and associated with substantial blood loss which is 
conventionally replaced with a donor blood transfusion. 
While often necessary and lifesaving, the use of donor 
blood is associated with increased risks of complications 
and adverse surgical outcomes. Intraoperative cell salvage 
(ICS) is a blood conservation strategy in which red cells 
collected from blood lost during surgery are returned to the 
patient thus minimising the use of donor blood. This is the 
protocol for a feasibility randomised controlled trial with 
an embedded qualitative study and feasibility economic 
evaluation. If feasible, a later definitive trial will test the 
effectiveness and cost-effectiveness of ICS reinfusion 
versus donor blood transfusion in ovarian cancer surgery.
Methods and analysis Sixty adult women scheduled for 
primary or interval ovarian cancer surgery at participating 
UK National Health Service Trusts will be recruited and 
individually randomised in a 1:1 ratio to receive ICS 
reinfusion or donor blood (as required) during surgery. 
Participants will be followed up by telephone at 30 days 
postoperatively for adverse events monitoring and by 
postal questionnaire at 6 weeks and 3 monthly thereafter, 
to capture quality of life and resource use data. Qualitative 
interviews will capture participants’ and clinicians’ 
experiences of the study.
Ethics and dissemination This study has been granted 
ethical approval by the South West–Exeter Research Ethics 
Committee (ref: 16/SW/0256). Results will be disseminated 
via peer-reviewed publications and will inform the design 
of a larger trial.
trial registration number ISRCTN19517317.
IntroduCtIon 
background
Ovarian cancer is the leading cause of 
death from gynaecological cancer in the 
UK (age-standardised mortality rate 9.1 per 
100 000, 2008–2010).1 Although survival rates 
have improved in recent decades, there are 
still more deaths from ovarian cancer than all 
other gynaecological cancers combined.2 The 
mainstays of treatment for advanced ovarian 
cancer are surgical cytoreduction and plati-
num-based chemotherapy. As operative success 
and survival is largely determined by residual 
disease.3 Surgery is often extensive with substan-
tial intraoperative blood loss, about 53% of 
patients lose more than 1.5 L during their first 
surgery.4 Blood lost during surgery is conven-
tionally replaced using donor blood transfu-
sion with the incidence of transfusion ranging 
from 35% to 77%.5 6 Perioperative donor blood 
transfusion is associated with increased risks of 
complications and adverse surgical outcomes 
including mortality, wound infection, pulmo-
nary and renal complications, systemic sepsis 
and prolonged hospital stay.7 In 2012, there 
were 12.3 serious adverse incidents per 10 000 
transfused components reported by the Serious 
Hazards of Transfusion (SHOT) group.8 SHOT 
is an independent, professionally led scheme, 
involved in collecting and analysing anonymised 
information on adverse events and reactions in 
strengths and limitations of this study
 ► This is the first study to use intraoperative cell sal-
vage in cytoreductive surgery for ovarian cancer.
 ► The study explores the feasibility and informs the 
design of a larger randomised controlled trial. 
Quantitative, qualitative and feasibility economic 
components are included.
 ► The effect of transfusion and cell salvage on im-
mune response to surgery is not assessed.
 ► This feasibility study will not provide information on 
the long-term outcomes of using either cell salvage 
or transfusion.
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blood transfusion from all healthcare organisations in the 
UK. Where risks and problems are identified, they produce 
recommendations to improve patient safety. One suggested 
explanation for adverse reactions is a general transient 
depression of the immune system following transfusion with 
blood products, transfusion-induced immunomodulation 
(TRIM).9 10 
Intraoperative cell salvage (ICS) or autologous blood 
transfusion is the practice of recovering red cells from 
blood lost in the operative field and returning them to 
the patient.11 This process involves the separation, centrif-
ugation, washing and filtration of heparinised red blood 
cells, before reinfusion into the patient. ICS eliminates or 
reduces the need for donor blood transfusion and its asso-
ciated risks, making it an alternative where major blood 
loss is anticipated.12 ICS can be available in theatre at 
modest expense and reduces dependence on the limited 
pool of banked blood. Studies comparing cell salvage 
with allogeneic blood transfusion (ABT) have demon-
strated increased mean erythrocyte (red blood cells) 
viability as high as 88% with cell salvage.13–15 ICS has been 
used successfully in surgical specialties16 including cardio-
thoracic, vascular, orthopaedic and hepatobiliary.17–20 In 
addition, ICS is associated with low rate of patient-re-
lated adverse events.21 ICS was initially contraindicated 
in cancer because of the theoretical risk of reintroducing 
malignant tumour cells into patients’ bloodstreams.22 23 
However, such concerns appear to be unfounded.24 The 
in vitro leucocyte depletion filters are highly efficient at 
removing malignant cells with removal rates of between 
80% and 100%.25 26 In patients undergoing surgery for 
gynaecological malignancy, leucocyte depletion filters 
effectively eliminate viable nucleated malignant cells 
from the returned blood.27 28 Far from compromising 
outcomes, ICS is associated with improved outcomes in 
cervical29 30 and oesophageal cancers.24
Interestingly, patients with primary metastatic cancer 
are known to have circulating tumour cells (CTC) in the 
blood.31 Furthermore, operative manipulation of tumours 
during surgery leads to peripheral blood concentrations 
of malignant cells many times higher than could be 
attained with cell salvage.32 The presence of CTC is preva-
lent in patients with cancer with approximately one CTC 
per 105 to 107 mononuclear cells found in the peripheral 
blood of patients with metastatic cancer.33
rationale
There is a paucity of studies in ICS, making it difficult for 
patients, clinicians and National Health Service (NHS) 
managers to make decisions about this technology.34 ICS 
has been used in patients with ovarian cancer in one of 
the participating sites with encouraging results, but a 
randomised controlled trial (RCT) is required for robust 
determination of effectiveness. The aim of a definitive 
trial would be to assess the clinical and cost-effectiveness 
of ICS for women undergoing cytoreductive surgery for 
ovarian cancer, compared with usual practice of trans-
fusing only allogeneic blood as required.
Aim and objectives
The aim of the study is to determine whether a definitive 
RCT is feasible and, if so, how best to deliver it. The objec-
tives of the study are to:
 ► Estimate the likely recruitment rate for the larger trial
 ► Estimate the likely completeness of resource use and 
outcome data
 ► Explore the practical logistics of undertaking rando-
misation in theatres
 ► Assess success of blinding of allocation for partici-
pants and outcome assessors
 ► Design data collection tools to collect resource use 
data from participants, hospital medical records and 
hospital staff
 ► Inform the trial design and confirm the resources 
required to run a larger definitive trial
 ► Explore the barriers and facilitators for women when 
deciding whether or not to participate
 ► Explore women’s perceptions of:
 – The intervention, the information given and ad-
vantages/disadvantages of participation so that in-
formation can be optimised for the larger trial
 – Other trial aspects, for example, regarding col-
lection of outcome measures and completing re-
source use questionnaires.
 ► Identify factors influencing surgeons’ decisions about 
whether or not to participate in the study.
MEthods
trial design
This is a protocol for a randomised, controlled, multi-
centre feasibility study in women undergoing cytoreduc-
tive surgery for ovarian cancer. Sixty participants will be 
individually randomised in a 1:1 ratio to ICS (reinfusion 
of their own blood) or donor blood transfusion during 
surgery. Participants and outcome assessors will be blinded 
to the intervention. All participants will be followed up by 
telephone for adverse events reporting at 30 days post-
operatively, by post 6 weeks postoperatively and 3 monthly 
thereafter as time allows. A schematic diagram of the 
trial is given in figure 1. The feasibility study includes an 
embedded qualitative component to assess participants’ 
(patients and clinicians) perceptions of their experience 
in preparation for the later trial. It will also involve an 
assessment of the feasibility of collecting resource use and 
other economic data for a future economic evaluation.
study setting
The study will take place at the Royal Cornwall Hospitals 
NHS Trust, Plymouth Hospitals NHS Trust, Gateshead 
Health NHS Foundation Trust and University Hospitals 
of Leicester NHS Trust. All sites have existing personnel 
experienced in the management of ICS and reinfusion.
Participants and recruitment
Participants will be recruited from patients scheduled 
to undergo surgery for ovarian cancer at the partici-
pating hospitals. Potential participants will usually be 
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identified from those patients attending the gynaecolog-
ical oncology outpatient clinic having been referred by 
their general practitioner under the 2-week wait cancer 
pathway. Some patients will be scheduled for primary 
surgery and are suitable for immediate recruitment to the 
study. Others will undergo neoadjuvant chemotherapy 
prior to interval debulking surgery and may be recruited 
to the study at a later date, following chemotherapy. 
Written informed consent (see online supplementary 
appendices 1 and 2) will be obtained by an appropri-
ately trained member of the research team in line with 
INTERNATIONAL CONFERENCE ON HARMONISA-
TION (ICH) Good Clinical Practice guidelines. As part 
of the consent process, patients will be reminded that 
they are free to withdraw from the study at any time 
without giving a reason and without affecting their future 
treatment.
Inclusion criteria
Potential participants must satisfy the following criteria to 
be enrolled in the study:
 ► 18 years old or over
Figure 1 Summary of trial design. ICS, intraoperative cell salvage .
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 ► Suspected or confirmed ovarian cancer (newly diag-
nosed) requiring cytoreductive surgery, whether 
primary or interval (following chemotherapy)
 ► CT scan evidence (with or without clinical evidence) 
compatible with FIGO stage III/IV ovarian cancer/
primary peritoneal cancer at presentation35 
(see online supplementary appendix 3)
 ► Eastern Cooperative Oncology Group performance 
status 0–136
 ► Willing to participate and able to give written informed 
consent
Exclusion criteria
Potential participants meeting any of the following 
criteria will be excluded from study participation:
 ► Diagnosis of concurrent malignancy
 ► Pregnant
 ► Haemoglobinopathies (eg, sickle cell, thalassaemia)
 ► Unwilling to accept donor blood (eg, on religious 
grounds)
randomisation
Randomisation will be undertaken after written consent 
has been obtained, but as close to the start of surgery as 
possible; usually, this will be on the morning of the oper-
ation day but if this is not possible for practical reasons, 
it may be performed earlier. Randomisation will be 
achieved by means of a web-based system created by the 
UK Clinical Research Collaboration-registered Peninsula 
Clinical Trials Unit (CTU) in conjunction with the trial 
statistician, using random permuted blocks of varying 
size. Participants will be allocated to receive ICS reinfu-
sion or donor blood transfusion in a 1:1 ratio, stratified 
by study site. To prevent any unnecessary delays in the 
operating theatre, cell salvage equipment will be set up in 
advance for all study participants, before confirmation of 
treatment allocation.
trial interventions
Participants will be allocated to receive either donor blood 
transfusion or ICS reinfusion intraoperatively, in accor-
dance with specified transfusion protocols. Donor blood 
will only be given (in standard volumes) when deemed 
necessary (eg, after substantial blood loss and/or drop in 
haemoglobin) whereas ICS blood will be returned even 
if only small quantities are lost. Some participants may 
not require any intraoperative transfusion and some (in 
either arm of the trial) may require donor blood transfu-
sion postoperatively.
Intraoperative cell salvage
All sites will follow a common ICS protocol and rele-
vant site staff will undergo study-specific training prior 
to the study start. Collected blood will be processed via 
the ICS machine before being reinfused via a leucode-
pletion filter. The make and model of ICS machine and 
leucodepletion filter used in clinical practice varies across 
NHS Trusts and will not be standardised for this feasi-
bility study. Relevant data from a local intraoperative cell 
salvage audit form will be transcribed into the study-spe-
cific case report form (CRF), including the amounts of 
salvaged blood processed and reinfused.
donor transfusion
Participants allocated to donor transfusion will be consid-
ered for transfusion during surgery in accordance with 
clinical judgement, guided by local hospital policy. The 
factors triggering transfusion (eg, excessive blood loss, 
hypotension, reduced Hb) will be documented in the 
CRF along with the amount and type of blood and blood 
products transfused.
donor transfusion in ICs arm
Participants allocated to the ICS arm who need donor 
transfusion can be given donor blood at any time, during 
or after surgery, for the duration of their hospital stay. 
The factors triggering intraoperative donor transfusion 
in the ICS group will be documented in the CRF as well 
as the amount and type of any blood and blood products 
transfused.
blinding
Surgeons, other theatre staff and the person recording 
details of intraoperative blood transfusion or reinfu-
sion cannot be blinded in this study. The research nurse 
responsible for recording postoperative outcomes will 
aim to remain blinded to treatment allocation. Partici-
pants in either arm of the study may have some form of 
blood replacement in progress immediately postsurgery; 
it is unlikely that participants will be able to distinguish 
between the two types and either group may require 
donor blood for clinical reasons.
Feasibility outcomes
The outcomes for this study are the feasibility and accept-
ability of the study and study procedures in relation to 
recruitment, randomisation, intervention, blinding, 
participant retention and data completion. Both quanti-
tative and qualitative methods will be used. Recruitment 
rate will be measured as the proportion of eligible patients 
who are subsequently enrolled and the number of patients 
recruited per site per month. The number of patients 
screened, number/per cent of patients approached, 
number/per cent of patients excluded after screening/
approach and the number/per cent of patients providing 
consent will be assessed. Reasons for declining participa-
tion will be sought where possible, and the appropriate-
ness and practicalities of the chosen eligibility criteria will 
be explored. The number/per cent of women enrolled 
prior to initial surgery compared with following neoadju-
vant chemotherapy will be assessed. The timing of rando-
misation in relation to operation start will be recorded to 
assess the practicalities of randomising as late as possible, 
in particular, what proportion are randomised on the day 
of surgery itself.
Use of ICS blood and donor blood will be recorded for 
both arms, partly to assess intervention fidelity but also 
to obtain an estimate of the proportion of people in the 
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control arm that actually require donor blood. Reasons 
for non-use of ICS blood and/or use of donor blood in 
the ICS arm will be recorded.
Since the intervention takes place in the operating 
theatre, it is unlikely that any participant will withdraw 
from intervention following randomisation. Attrition will 
be assessed by examining the number of participants lost 
to follow-up at any subsequent point in the study period. 
Reasons for discontinuation of follow-up will be sought 
from participants.
The success of blinding of allocation for participants 
and outcome assessors will be assessed by asking both the 
participant and research nurse to guess the allocation 
(including ‘unsure’) at the 30-day postoperative follow-up 
and comparing the responses with the actual allocation.
Clinical outcomes
In the later, definitive trial, our primary outcome is likely 
to be either mortality or cancer recurrence, both of which 
are unlikely to occur in the time available in this feasi-
bility study. Therefore, while readily accessible, these data 
will not be collected here. Other measures proposed for 
the later trial will be collected in this feasibility study at 
baseline and perioperatively, with follow-up at 30 days 
and 6 weeks postoperatively. Participants recruited at an 
early stage of the study will also be followed up at 4.5, 7.5 
and 10.5 months postoperatively as time allows (figure 1). 
Clinical outcomes include:
 ► Inadvertent visceral injury (bladder, bowel, ureters, 
blood vessels, nerve)
 ► Return to theatre within 48 hours
 ► Surgical site infection (see online supplementary 
appendix 4) within 30 days
 ► Thromboembolic complications (DVT, PE) within 30 
days
 ► Number and nature of adverse events
 ► Amount of donor blood given (total and ≤24 hours 
postsurgery)
 ► Length of hospital stay
 ► Resource use
 ► Generic quality of life (QOL) measure: EQ-5D-5L
 ► Cancer-specific QOL measure: EORTC QLQ-C30 
(Version 3.0) (confirmed cancer only)
 ► Ovarian cancer QOL measure: EORTC QLQ-OV28 
(confirmed cancer only)
data management
Each participant will be allocated a unique trial number 
on consenting to the study and will be identified in all 
study-related documentation by her trial number and 
initials. A record of names and addresses linked to partic-
ipants’ trial numbers will be maintained by the research 
nurse at each site for administrative purposes, and stored 
securely.
data collection
Data collected by the research team (table 1) up to 30 
days postoperatively will be recorded on study-specific 
data collection forms (CRFs), usually by a research nurse. 
All data not routinely captured during the hospital admis-
sion but recorded straight into the CRF will be classified 
as source data. Participant self-completion question-
naires at baseline will be completed during a face-to-face 
meeting with a research nurse, following written informed 
consent. The research nurse will return completed CRFs 
and baseline questionnaires to the CTU. Subsequent 
self-completion questionnaires (6 weeks postoperatively 
Table 1 Trial schedule
Operation and perioperative data collection 
Preoperative Postoperative follow-up
Screen Baseline
1 2 3† 4† 5†
30 days 
postop
6 weeks 
postop
3 months 
after follow-
up 2
6 months 
after follow-
up 2
9 months 
after follow-
up 2
Screen/eligibility x
Consent x
Demographics and 
history
x
Randomisation x
EORTC QLQ-C30* x x x x x
EORTC QLQ-OV28* x x x x x
EQ-5D-5L x x x x x
Adverse events x
Resource use 
questionnaire
x x x
Qualitative interviews x x
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and 3 monthly thereafter as time allows) will be mailed 
to participants directly from the CTU and returned by 
participants to the CTU in a prepaid envelope provided. 
In the event of non-return of a questionnaire, a reminder 
will be sent from the CTU in the first instance. If there is 
no response from the two mailings, the CTU will inform 
the local research nurse who will telephone the partici-
pant in order to encourage compliance with follow-up.
statistical considerations
Sample size for a feasibility study is necessarily a compro-
mise between the twin assets of precision and efficiency. For 
any binary ‘outcome’, our target sample size of 60 will result 
in a 95% CI of no greater than about +/−12 percentage 
points, while in a single arm, the target of 30 will have a 
CI of no more than +/−17 percentage points.
Data analysis will enable the feasibility outcomes 
to be addressed in order to inform a decision about 
proceeding to a definitive trial. Data will be presented in 
accordance with the extension to the Consolidated Stan-
dards of Reporting Trials statement for pilot and feasi-
bility studies. They will detail the numbers of patients 
that were approached, the number that were eligible 
and the number providing consent. Likewise, compli-
ance rates at all stages will be presented, including the 
numbers of questionnaires completed at each stage and 
more generally the completeness of data on all outcomes 
at each time point. Participating patients’ characteris-
tics (demographics, comorbidities, clinical details) will 
be summarised and, where possible, compared with the 
overall population of relevant patients to explore possible 
factors associated with participation. Where possible, the 
reasons will be ascertained for potentially eligible patients 
not being approached to consider participation.
Descriptive data on the clinical outcomes will be 
presented by trial arm, using appropriate measures of 
central tendency and variation for continuous measures 
and numbers/percentages for categorical measures. No 
formal statistical tests will be conducted.
Qualitative study
A qualitative evaluation will assess the acceptability of 
the intervention to women taking part in the study, in 
particular attitudes towards reinfusion of salvaged blood 
and transfusion of donor blood. The study will also gain 
an understanding of the women’s experience of taking 
part in the research processes of the TIC TOC study and 
what influenced their decision to take part. Following 
surgery, up to 20 women from across all centres will be 
asked to take part in individual face-to-face or telephone 
semistructured interviews using a topic guide that has 
been developed with patient and public involvement 
(PPI) involvement (see online supplementary appendix 
5). Purposive sampling techniques will ensure a range of 
women are selected according to centre, education, age, 
ethnicity, socioeconomic status and social support.
As the trial schedule allows, the same women will be 
approached to take part in a brief telephone interview 
3 months after the first interview. The purpose of the 
second interview is to determine participants’ percep-
tions about the follow-up research processes and ask 
their opinion about whether anything should change in 
a full trial. Surgeons from each centre will also be invited 
to participate in one brief telephone interview each to 
understand the issues considered in deciding whether to 
offer women the opportunity to take part in the study.
The qualitative data will be managed using computer soft-
ware such as Nvivo 11 and thematically analysed.37 38 The 
researcher will ensure accuracy of the transcription and 
read the transcript several times to become immersed in 
the data, noting initial thoughts and ideas. Codes will be 
assigned to extracts of the data relevant to the project. Codes 
with similar meaning will be grouped together in themes. 
Using constant comparison techniques across the tran-
scripts’ themes looking for similarities and differences, the 
themes will be reviewed and refined. Extracts from the data 
will be used in the final report. Reflexive research memos 
will be used as an audit trail of the analysis procedure.39 A 
second qualitative researcher will conduct an independent 
analysis of a subset of six transcripts before the researchers 
meet to discuss and agree the findings. Findings will also be 
presented to the study’s patient advisory group for discus-
sion. Any significant differences of opinion will be discussed 
with the chief investigator. A model may be developed to 
explain the factors affecting recruitment and retention to 
the trial to inform development of the research processes 
required in any future full trial.
Economic data and analyses
A definitive study will include a within-trial economic 
evaluation to compare costs and health outcomes of ICS 
versus donor blood within the time frame of the study and 
a decision analytic model to extrapolate any future health 
benefits and costs to the lifetime of the participant. The 
evaluations will primarily be in relation to quality-adjusted 
life-years and will take a health and social perspective on 
costs, in accordance with National Institute of Health and 
Care Excellence (NICE) guidelines.37 Secondary analyses 
will take place in relation to important clinical outcomes 
of interest for the definitive trial such as deaths averted 
and disease-free progression. This study aims to test the 
feasibility of collecting enough resource use and outcome 
data to perform the future economic evaluations.
Data collection tools will be prepared and refined with 
a view to undertaking the two planned economic evalua-
tions within the future study. These evaluations will take 
on a health and social care payer perspective. Should 
participant-reported resource use data allow, the future 
within-trial economic evaluation will take on a societal 
perspective on costs in secondary analyses, to further 
capture the burden to participants, carers and society. 
The parameters for the lifetime economic decision model 
(costs, outcomes and probabilities of outcomes to occur) 
will be informed by the within-trial economic results. If 
feasible, costs from a societal perspective may be included 
in the lifetime economic decision model as well.
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Resources will be collected from several sources. In 
the immediate postoperative period, research nurses 
will record resources pertaining to the participant’s 
surgery and subsequent hospital stay. Where possible, 
research staff will also review participants’ medical notes 
at 4.5 months postoperatively to collect hospital contacts 
following initial discharge (ie, rehospitalisations, outpa-
tient and emergency visits). Participant-completed 
resource use questionnaires will be administered at both 
6 weeks and 4.5 months postoperatively (where the trial 
schedule allows) to collect other resources used. These 
questionnaires will be delivered by post and include ques-
tions related to inpatient and outpatient hospital visits; 
community-based services such as general practice doctor 
and nurse contacts, physiotherapy, occupational therapy 
and other community contacts; use of personal social 
services such as home care workers and social workers; 
privately paid therapies and expenses; time off work and 
lost leisure; and informal care required from family and 
friends. Completion rates, missing data and the method 
of administering questionnaires will be reviewed to iden-
tify potential problems with data collection methods 
and to seek solutions to minimise participant/staff 
burden if required. We will report frequency, mean and 
SD of resources used by trial arm to explore potential 
cost drivers for the main study.
The EuroQoL EQ-5D questionnaire will capture 
generic QOL differences between the trial arms. In 
a recent study of EQ-5D valuation sets, the 3 L and 5 L 
versions of the EQ-5D produced substantially different 
estimates for cost-effectiveness40 and prompted NICE to 
issue a position statement in August 2017 to recommend 
the future use of the 3 L version.41 In this study, we will use 
the mapped utility scores from the 3 L to the 5 L version 
using the Van Hout algorithm42 for the UK population, as 
recommended by the NICE statement. We expect to use 
the 3 L version in the future study and not proceed with 
the study of the distribution properties produced by the 
5 L version scores in this feasibility study.
PPI and engagement
The study has benefitted from its inception from an 
enthusiastic patient advisory group. The aim of PPI in the 
study is to ensure that the trial is equitable and acceptable 
to the women taking part by embedding the women’s 
experiential expertise of cancer throughout the trial 
design and processes. The group comprises six women 
aged between 50 and 80 years, who have experienced a 
cancer diagnosis and are living in Cornwall. However, 
one member is formerly from Gateshead, where she was 
treated for her cancer, so she is able to bring her experi-
ence of the patient pathway to inform the trial processes 
across the sites. Another member and coapplicant is the 
founder of PANTS cancer charity in Cornwall.
The PPI work is undertaken using a predominately 
collaborative approach with engagement functions 
embedded within it. The members worked with the 
research team on the research design and in particular 
the patient approach, providing input into the grant 
application, language, content and layout of the partic-
ipant documentation. The group have worked on the 
qualitative interview topic guide content and are also 
working with the qualitative researchers on analysis of 
the participant interview transcripts. The members are 
fully integrated into the team and regularly attend the 
trial management meetings, as well as provide advice and 
suggest solutions to problems encountered during the 
trial.
The members will attend patient and public events 
and conferences to engage with other members of the 
public and professionals and share their experience of 
supporting and being part of the design and management 
of research. They will also work together with the wider 
research team to prepare a lay summary of the findings 
and on other communications such as website, Twitter 
and Facebook articles.
All members of the research team contribute to the 
training and support of the PPI members. The mecha-
nisms to achieve these are multifactorial and include 
specific discussion around methodology and trial 
processes in PPI meetings, explaining the terminology 
in lay language, providing information, such as the 
INVOLVE jargon buster sheet, and conducting work-
shops for specific tasks (eg, poster development), as well 
as signposting to other resources such as the INVOLVE 
website.
EthICs And dIssEMInAtIon
The results of this feasibility study will be published 
in peer-reviewed journals and presented at relevant 
national/international conferences and to patient 
groups. Participants of the trial will be sent a summary of 
the findings and these will also be disseminated via the 
pantscancer. org charity, Target Ovarian Cancer charity 
and participating NHS Trusts’ websites.
dIsCussIon
Research has shown that donor blood transfusions have 
been associated with poorer outcomes including increased 
mortality, wound, pulmonary and renal complications; 
this has been ascribed to TRIM9 which is a transient 
depression of the immune system following transfusion 
with blood products. The Cochrane meta-analysis of 
randomised trials estimated perioperative ABT to be asso-
ciated with increased risk of recurrence with OR of 1.42 
(95% CI 1.20 to 1.67) in surgery for colorectal cancer.43 
Long-term results from a clinical trial suggest that this 
effect of ABT is persistent.44 45 This led to the suggestion 
of introducing measures that would help limit the use of 
ABT.12
Patient blood management is an evidence-based 
patient-tailored approach aimed at reducing the need for 
ABT by managing anaemia, perioperative blood conser-
vation, surgical haemostasis and drug use.46 Perioperative 
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blood conservation measures include interventions such 
as the administration of agents to diminish blood loss 
(eg, tranexamic acid, fibrin sealant), agents that promote 
red blood cell production (eg, erythropoietin) and tech-
niques for reinfusing a patient’s own blood including 
cell salvage.28 Previous randomised and non-randomised 
studies have provided evidence that the use of ICS can 
reduce the need for ABT.9 A systematic review of 75 
randomised trials highlighted that salvaged blood reinfu-
sion reduced the rate of exposure to ABT by 38% (rela-
tive risk, 0.62; 95% CI 0.55 to 0.70).47 However, concern 
exists that blood collected by ICS might result in reinfu-
sion of tumour cells and subsequent distant metastases 
thus limiting the use of cell salvage across oncological 
specialties. However, in patients undergoing surgery 
for a gynaecological malignancy, the use of a leucocyte 
depletion filter was shown to be effective in eliminating 
viable nucleated malignant cells from the returned blood 
during collection, processing and leucofiltration.27 Simi-
larly, in vitro work shows that depletion filters are highly 
efficient at removing malignant cells, leading to removal 
rates of between 80% and 100%.25 26
Patients with primary or metastatic cancer are known 
to have CTCs in the blood. The concentration of CTCs 
varies widely depending on tumour type and stage of 
disease.31 There is evidence from a range of different 
cancer surgeries that operative manipulation of tumour 
during surgery leads to peripheral blood concentrations 
of malignant cells many times higher than could be 
attained with cell salvage alone.31 32 48
There is emerging evidence suggesting that far from 
compromising outcomes, intraoperative autologous trans-
fusion is associated with improved outcomes in surgery 
for other gynaecological cancers such as cervical cancer. 
Several studies in patients with early stage (I–IIA) cervical 
cancer report that intraoperative autologous transfusion 
significantly reduces the need for donor blood transfu-
sion, without compromising survival or postoperative 
complication rates.30 In addition, no distant recurrences 
have been reported.30 However, most of the evidence on 
the use of salvaged blood in cancer surgery is based on 
retrospective and observational studies. These studies are 
insufficient to draw any definitive conclusions regarding 
adverse events related to a particular intervention in the 
presence of multiple confounding factors. Therefore, in 
order to mitigate for confounding factors, a large well-de-
signed RCT is required.49 Our trial provides new evidence 
in the use of cell salvage in ovarian cancer surgery and 
will add to a more general evidence base informing the 
use of ICS in other areas, in particular other cancers.
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